Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Significant Increase in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDT) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 120,800 shares, an increase of 260.6% from the August 31st total of 33,500 shares. Based on an average daily volume of 232,500 shares, the short-interest ratio is presently 0.5 days.

Hedge Funds Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC purchased a new position in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies at the end of the most recent quarter. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Price Performance

Shares of Helius Medical Technologies stock traded down $0.01 during midday trading on Friday, reaching $0.67. The company had a trading volume of 98,823 shares, compared to its average volume of 335,335. The stock has a fifty day moving average price of $0.77 and a 200 day moving average price of $2.21. The firm has a market cap of $2.41 million, a PE ratio of -0.05 and a beta of 1.61. Helius Medical Technologies has a fifty-two week low of $0.65 and a fifty-two week high of $9.89.

Helius Medical Technologies (NASDAQ:HSDT) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.14). Helius Medical Technologies had a negative return on equity of 258.06% and a negative net margin of 1,487.54%. The company had revenue of $0.18 million during the quarter. During the same quarter in the prior year, the company posted ($3.00) earnings per share.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.